Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110 020 (INDIA) T: +91-11- 33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN: L 40300DL1995PLC066923



Date: 25th September, 2025

Scrip Code: - 531768

The Manager, BSE Limited, Department of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, Mumbai- 400001. Scrip Code:- POLYMED

The Manager National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1-Block-G Bandra Kurla Complex, Bandra(E), Mumbai-400051.

Sub: Submission of Revised Investor's Presentation on Acquisition of "Citieffe Group"

Dear Sir/Madam,

In continuation to our intimation on yesterday i.e. 24th September, 2025 and pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Revised Investor's Presentation on Acquisition of "Citieffe Group".

The same is also available on the website of company i.e. www.polymedicure.com.

Request you to take the same on records.

Thanking You, Yours Sincerely

For Poly Medicure Limited

Avinash Chandra Company Secretary M. No. A32270







Acquisition of Citieffe

Our Pathway to Global Orthopaedic Market

Investor Presentation

September 2025



Polymed: India's Leading MedTech Company

Polymed at a Glance

























Navigating the Path


Building Tomorrow's Healthcare Solutions





Our Innovations Deliver Care to Key Clinical Specialties







Polymed's Manufacturing Footprint

12 Facilities across 3 continents




























Company with international manufacturing facilities

350+ Moulding Machines and 1500+ Molds & Dies

200+ Automatic Assembly Machines

100+ Robots employed in our manufacturing processes



Way Forward



Research & Development



Emphasizing Inorganic Growth

Strategic Alliances to foster synergies and expanding market reach



International Strategy

Improve brand visibility & enhance direct presence to gain deeper insights into local market dynamics

 Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations

Integration of AI and IoT technologies to enhance efficiency & precision



Manufacturing

Enhance manufacturing capacity to meet growing global demand



Clinical Footprint

Targeted clinical engagements with key stakeholders, fostering innovation and enhancement of patient outcomes



Protect Our Planet

Implementing sustainable practices across all operations, aiming to minimize environmental impact



Robust Growth Backed by Solid Balance Sheet...

Amount in INR Cr.



^{*} Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds






Citieffe: Our Pathway to Global Orthopaedic Market

Executive Summary

Brief Overview	 Founded in 1962 Citieffe is a vertically integrated developer, manufacturer and distributor of Trauma and Extremity fixation systems with direct sales footprint in Italy, US and Mexico Entire product portfolio is EU MDR compliant Strong R&D capabilities with 45 patents, primarily on transverse features for significant product differentiation Strong management team in place with long association with the company Citieffe Financials: CY24 Revenue: EUR 17.3 million I EBITDA: EUR 3.1 million; Revenue and EBITDA growth of 15% and 14% respectively on year-on-year basis
Products	 Internal Fixators: Estremo nails (Tibia & Femoral Nail), EBA systems (Femoral Nail), DT Humerus (Humerus bone), Rondo Screws External Fixators: Dolphix, F4- Elbow & Knee, Rekrea, Xframe General Instruments & Other: Navigation System
Transaction Overview	 Acquiring Medistream SA ("Group") consisting Citieffe SRL and its step-down subsidiaries in USA & Mexico Existing Management to continue post transaction; Mr. Pascal Govi to continue as CEO Acquiring 100% of the company (majority stake with Archimed; a Europe based healthcare focused PE fund) Equity valuation of ~Euro 18.8mn; shareholder loan liabilities of Euro 4.2mn to be repaid; total upfront payout of ~Euro 23mn; taking over net external debt of Euro 8.1mn With Enterprise Value of EUR 31 million, the transaction values company at EV/EBITDAx of 10.2x (FY 24 basis)
Status and Next Steps	 Customary transaction closure activities to be completed including closing adjustments Expected to be closed in next 4-8 weeks To be funded by cash balances and internal accruals




Orthopaedics presents a large TAM with Trauma & Extremities growing fastest



Key Growth Drivers for Orthopaedic market


- Ageing Population
- Increasing Prevalence of Musculoskeletal Disorders & Joint Disorders
- Rise in Trauma and Sports-Related Injuries
- Technological Innovation & Advanced Surgical Techniques
- Growing Healthcare Expenditure & Improving Access
- Regulatory & Reimbursement Support

Orthopaedic market by Geography



- The US accounts for 67% of the market, followed by EMEA and APAC. However, APAC is set to grow the fastest
- India constitutes 3% of global orthopedic devices market and is one of the largest market in Asia after China and Japan

Global Ortho market share (2024E)




Top 5 players controlling > 60% of Global Market




The Trauma & Extremities market: Fastest growing and greater resilience

Global Trauma and Extremities market evolution (USD Bn)




- Extremity growth driven by technological advancements in developed markets
- Growth stemming from developing countries for Trauma


Trauma & Extremity market by Segment



Trauma market share (2024E)



Trauma & Extremity market by Geography





Citieffe – fully integrated Trauma and Extremity supplier with global sales footprint

Vertically integrated developer, manufacturer and distributor of Trauma and Extremity fixation systems ...

Founded in 1962 near Bologna; 109 employees

45+ patents.
Dedicated R&D team
of 6 FTEs

54+ KOL across globe from leading institutions


MDR clearance on the full portfolio with inhouse manufacturing in Italy

Low customer complaint rate with defective product rate lower than 0.001%

Unique navigation software for nailing systems

€17.3 MlnCY '24 Revenue
(15% y-o-y growth)

€3.1 Mln*CY '24 EBITDA
(14% y-o-y growth)



... with global presence. Approx. 85% of sales coming from countries with direct sales force presence

#2 independent player in Italy with a c.12%+ market share

One of the Top players in Mexico with 12% + market share² Geographical coverage of 25+ countries with 25+ distributors

Led by strong and experienced management ...

P. Govi – CEO

In Citieffe since 2019

~34+ years of work experience

E. Cocchi - CFO

In Citieffe since 2021

~26+ years of work experience

M. Rambola'- Global Supply Chain Director & GM USA

In Citieffe since 2020

~18+ years of work experience

R. Fernandez – GM México and LATAM sales director

In Citieffe since 2018

~25+ years of work experience

A. Dovesi - R&D Director

In Citieffe since 1987

~30+ years of work experience



^{1.} Excluding plates; 2. Excluding Plates and low cost products Source: Industry Reports, company estimates

^{*} Excludes one off /extraordinary expenses and income

Integrated operations allow flexible production, shorter lead times & greater profitability

R&D / Product development

- Dedicated R&D team of six FTEs; R&D spend of ~5% of revenue per year
- 45+ transversal patents with multiple unique-to-market products
- Relationship with KOLs help develop new products though feedback mechanism

Regulatory Approval

Rigorous regulatory clearance from various authorities to obtain the official qualification for products (CE, FDA, etc.)

Sourcing and purchases

Long term relationships with key suppliers

In-house Production

- Production through dedicated machinery and experienced and specialised workforce
- > In-house clean room and sterile packaging capabilities
- > Sterilisation currently outsourced but plan to build internal capability soon

Sales & Marketing

Integral Rusiness |

Model

- > Citieffe has direct presence in Italy, USA, Mexico ensuring direct access to the markets; 85% of revenue generated from these markets
- Global distribution network managed through inhouse team





Manufacturing Facility Overview

















ISO 9001 & ISO 13485 approved manufacturing

2 production facilities:

Site 1 – Production facility, total area of 1,000 m², with total 12 machines

Site 2 – Assembly & packaging facility, total area of 1,100 m² with a total of 10 machines

Semi-finished goods are received from Site 1 & assembled at site 2, then cleaned & packaged & sent to customers

Facility currently runs at 60% capacity, with the ability to add a third shift to cover the forecast ramp up in sales



Citieffe product portfolio, powered by strong R&D and globally accredited quality

Areas Covered by Portfolio

Products Category

Products

R&D Capabilities



Tibia

Femur


Internal **Fixators**

External **Fixators**


Navigation Systems and Instruments

Made in Italy









- A dedicated R&D team of six FTEs
- R&D products pipeline with 3 – 5 new products released each year
- Low customer complaint rate, with a defective product rate of lower than 0.001%

Accreditation

The portfolio is accredited in Europe, the USA & Key Latin American markets. Products registered in 25+ countries








(Whole Portfolio)



Direct Sales presence in Italy, USA & Mexico





Potential Synergy from the Acquisition





Portfolio Expansion

- Polymed will add
 Plates in near term
- To enter joints replacement market in medium term





US Expansion

Hire more sales reps in US to increase coverage in largest Ortho market wherein prices are also premium to Europe





Make in India

Reduce cost of production by outsourcing part of manufacturing process and building capabilities in India





Expand in India

Introduce Citeffe products in India and expand by leveraging Polymed extensive network





Distribution network

Deepen presence in Europe while expanding to rest of the world through leveraging Polymed's distribution network

Synergy realisation through product and distribution expansion as well as manufacturing outsourcing



Strategic rationale behind the acquisition

Large Global TAM



Provides platform for expanding into attractive orthopaedics segment specifically focused in the fastest-growing extremities sub-segment; **platform to build a global orthopedic business**

Differentiated portfolio



A diverse, fully accredited and patented portfolio of trauma & extremity products. It has 45 patents and full EU MDR clearance and accreditation in key markets like USA (FDA)

Global Presence



Direct sales presence in Italy, USA and Mexico. #2 independent player in Italy with a c.12%+ market share. One of the Top players in Mexico with 12% + market share and growing presence in US, the largest orthopaedic market

Integrated Business Solution



Citieffe has inhouse capabilities from product R&D to manufacture to sales and distribution. Agile product development leading to quick to market innovations

Synergy



Boost financial performance by **leveraging Polymed's manufacturing expertise and global distribution network**. **Product portfolio expansion** to enhance addressable market size.

Growth Potential



A resilient and profitable business in a growing orthopaedic segment (Trauma & Extremities) with ability to enter orthopaedics adjacencies through strong in-house R&D. Also offers significant potential to scale-up US business wherein prices are premium to Europe

Strong Financials



Citieffe's EUR 17.3M revenue and EUR 3.1M EBITDA (CY '24) with 15%/14% y-o-y growth provides a proven, scalable platform.



Thank You

Poly Medicure Limited

Registered Office:

232 B, 3rd Floor, Okhla Industrial Estate, Phase

III, New Delhi-110020, India

Tel:- 91-11-33550700, 47317000, 26321838/99

For any general queries, Reach us at:

info@polymedicure.com

Visit: www.polymedicure.com

